Drug intelligence / Profile preview

polymyxin b + gentamicin + amphotericin b + nystatin + vancomycin

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Topical, Oral, Inhalation

Overview

A combination antimicrobial preparation containing five active ingredients: polymyxin B (a polymyxin antibiotic effective against gram-negative bacteria), gentamicin (an aminoglycoside antibiotic active against gram-negative bacteria), amphotericin B (an antifungal agent), nystatin (an antifungal agent), and vancomycin (a glycopeptide antibiotic effective against gram-positive bacteria). This combination provides broad-spectrum coverage against gram-positive bacteria, gram-negative bacteria, and fungi.

Targets

Bacterial 30S ribosomal subunit decoding center / A-site of 16S rRNAD-Ala-D-Ala (D-Ala-D-Ala terminus)Ergosterol

Beyond the preview

Go deeper on polymyxin b + gentamicin + amphotericin b + nystatin + vancomycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on polymyxin b + gentamicin + amphotericin b + nystatin + vancomycin.

Explore the full profile